147 related articles for article (PubMed ID: 38662170)
1. Peripheral NK cells identified as the predictor of response in extensive-stage small cell lung cancer patients treated with first-line immunotherapy plus chemotherapy.
Cui Y; Chen Y; Zhao P; Li S; Cheng Y; Ren X
Clin Transl Oncol; 2024 Apr; ():. PubMed ID: 38662170
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study.
Qin B; Xin L; Liang C; Li L; Song Q; Long Y; Zhang X; Wang D; Shi W; Zhang J; Hu Y; Yang B; Xiong Q
BMC Cancer; 2024 Jan; 24(1):100. PubMed ID: 38233798
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of first-line immunotherapy plus chemotherapy in treating patients with extensive-stage small cell lung cancer: a Bayesian network meta-analysis.
Zhang T; Li W; Diwu D; Chen L; Chen X; Wang H
Front Immunol; 2023; 14():1197044. PubMed ID: 37435087
[TBL] [Abstract][Full Text] [Related]
5. Assessing treatment outcomes of chemoimmunotherapy in extensive-stage small cell lung cancer: an integrated clinical and radiomics approach.
Zhao J; He Y; Yang X; Tian P; Zeng L; Huang K; Zhao J; Zhou J; Zhu Y; Wang Q; Chen M; Li W; Gao Y; Zhang Y; Xia Y
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730276
[TBL] [Abstract][Full Text] [Related]
6. A retrospective real-world experience of immunotherapy in patients with extensive stage small-cell lung cancer.
Qiu G; Wang F; Xie X; Liu T; Zeng C; Chen Z; Zhou M; Deng H; Yang Y; Lin X; Xie Z; Sun G; Zhou C; Liu M
Cancer Med; 2023 Jul; 12(14):14881-14891. PubMed ID: 37462138
[TBL] [Abstract][Full Text] [Related]
7. Real-World Efficacy and Safety of Thoracic Radiotherapy after First-Line Chemo-Immunotherapy in Extensive-Stage Small-Cell Lung Cancer.
Xie Z; Liu J; Wu M; Wang X; Lu Y; Han C; Cong L; Li J; Meng X
J Clin Med; 2023 Jun; 12(11):. PubMed ID: 37298023
[TBL] [Abstract][Full Text] [Related]
8. Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer: a systematic review and meta-analysis.
Lin Y; Jiang W; Su CY; Pan XB
Aging (Albany NY); 2023 Sep; 15(18):9561-9571. PubMed ID: 37724893
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
Yang Y; Ai X; Xu H; Yang G; Yang L; Hao X; Yang K; Mi Y; Wang G; Zhang S; Lei S; Wang Y
Thorac Cancer; 2022 Dec; 13(23):3295-3303. PubMed ID: 36218023
[TBL] [Abstract][Full Text] [Related]
10. Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.
Ding X; Cao H; Chen X; Jin H; Liu Z; Wang G; Cai L; Li D; Niu C; Tian H; Yang L; Zhao Y; Li W; Cui J
J Transl Med; 2015 May; 13():158. PubMed ID: 25968637
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of first-line PD-L1/PD-1 inhibitors in limited-stage small cell lung cancer: a multicenter propensity score matched retrospective study.
Xie J; Xu K; Cai Z; Chen M; Jiang Y; Ye J; Lin X; Lv T; Zhan P
Transl Lung Cancer Res; 2024 Mar; 13(3):526-539. PubMed ID: 38601454
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety comparison of PD-1 inhibitors
Yang G; Sun H; Sun N; Huang W; Wang Z; Zhang H; Liu C
J Thorac Dis; 2022 Dec; 14(12):4925-4937. PubMed ID: 36647464
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of PD-L1 Inhibitors plus Chemotherapy versus Chemotherapy Alone in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: A Retrospective Real-World Study.
Qu J; Kalyani FS; Shen Q; Yang G; Cheng T; Liu L; Zhou J; Zhou J
J Oncol; 2022; 2022():3645489. PubMed ID: 36199793
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of PD-(L)1 inhibitor plus chemotherapy versus chemotherapy as first-line treatment in extensive-stage small-cell lung cancer.
Lu J; Lei X; Zhang P; Du L; Zhang Z; Qu B
Cancer Med; 2023 Sep; 12(17):17924-17933. PubMed ID: 37563966
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis.
Chen CY; Chen WC; Hung CM; Wei YF
Immunotherapy; 2021 Oct; 13(14):1165-1177. PubMed ID: 34261336
[TBL] [Abstract][Full Text] [Related]
16. Comparison of efficacy and safety between PD-1 inhibitors and PD-L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysis.
Wang Y; Li L; Hu J; Zhao Y; Yan H; Gao M; Yang X; Zhang X; Ma J; Dai G
BMC Cancer; 2023 Dec; 23(1):1196. PubMed ID: 38057736
[TBL] [Abstract][Full Text] [Related]
17. Consideration of Surrogate Endpoints for Overall Survival Associated With First-Line Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Zhang S; Li S; Cui Y; Zhao P; Sun X; Cheng Y
Front Oncol; 2021; 11():696010. PubMed ID: 34336683
[TBL] [Abstract][Full Text] [Related]
18. Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE).
Salama JK; Gu L; Wang X; Pang HH; Bogart JA; Crawford J; Schild SE; Vokes EE; Ready NE
J Thorac Oncol; 2016 Mar; 11(3):361-9. PubMed ID: 26723241
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
Front Oncol; 2022; 12():894835. PubMed ID: 36203439
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]